Healthcare / Pharmaceutical RetailersNasdaqCM
$2.43
-0.02 (-0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 27% · confianza 25%
FCF escenarios
weak_data · normalized FCF $14.6M · quality 28.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$214M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-57.9%
↓Gross Margin
25.8%
↓Debt/Equity
1.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.5%
FCF CAGR
—
FCF margin
2.2%
FCF / Net income
-0.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $594.0M · net income $-50.7M · FCF $13.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $594.0M | $594.0M | $522.3M | $487.7M | $356.9M |
| Net Income | $-50.7M | $-50.7M | $-4.3M | $-39.3M | $-71.8M |
| EBITDA | $-13.7M | $-13.7M | $33.8M | $-4.2M | $-33.6M |
| EPS | -0.62 | -0.62 | -0.05 | -0.53 | -1.14 |
| Gross Margin | 25.8% | 25.8% | 27.3% | 26.9% | 28.3% |
| Operating Margin | 2.6% | 2.6% | 2.9% | -0.5% | -5.6% |
| Net Margin | -8.5% | -8.5% | -0.8% | -8.1% | -20.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.70 | 1.70 | 0.52 | 0.55 | 0.45 |
| Current Ratio | 1.43 | 1.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.2M | $13.2M | $25.8M | $14.6M | $-4.6M |
| Returns | |||||
| ROE | -57.9% | -57.9% | -3.0% | -29.9% | -45.9% |
| Valuation | |||||
| EV/EBITDA | — | — | 7.65 | — | — |
| P/B | 2.28 | 2.28 | 1.61 | 0.85 | 0.55 |
| Growth & Yield | |||||
| Revenue Growth | 13.7% | 13.7% | 7.1% | 36.7% | — |
| EPS Growth | -1140.0% | -1140.0% | 90.6% | 53.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.62
Residual
+8.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.